An Update on the Safety and Efficacy of Corneal Collagen Cross-Linking in Pediatric Keratoconus

Area of Science:

• Ophthalmology
• Corneal Diseases
• Regenerative Medicine

Background:

• Keratoconus is a progressive corneal disease affecting young individuals, causing irregular astigmatism and vision loss.
• Halting disease progression is crucial for managing keratoconus and preserving vision.
• Corneal collagen cross-linking (CXL) is a proven treatment for stabilizing adult keratoconus.

Purpose of the Study:

• To review the literature on the use of corneal collagen cross-linking in pediatric keratoconus patients.
• To evaluate the safety and efficacy of CXL in children.
• To highlight the need for further research into alternative CXL protocols for pediatric populations.

Main Methods:

• Literature review of studies investigating corneal collagen cross-linking in pediatric keratoconus.
• Analysis of safety and efficacy data from clinical studies.
• Assessment of outcomes in children compared to adult populations.

Main Results:

• Standard CXL demonstrates a good safety and efficacy profile in children with keratoconus.
• The treatment effectively halts disease progression in pediatric patients over follow-up periods up to three years.
• Pediatric keratoconus often presents with greater severity and faster progression than in adults.

Conclusions:

• Corneal collagen cross-linking is a safe and effective option for managing progressive keratoconus in children.
• Further investigation into transepithelial and accelerated CXL protocols is warranted to improve compliance in pediatric patients.
• Standard CXL provides a valuable therapeutic option for pediatric keratoconus, comparable to adult outcomes.